Jun Miyazaki

List of Publications by Year
in descending order

51	940	567281 15	477307 29
papers	citations	h-index	g-index

62	62	62	1413
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Japanese linguistic validation of the ureteral stent symptom questionnaire. International Journal of Urology, 2022, , .	1.0	0
2	Clinical features of multiply recurrent retroperitoneal liposarcoma: A single-center experience. Asian Journal of Surgery, 2021, 44, 380-385.	0.4	12
3	The liposome of trehalose dimycolate extracted from M.Âbovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells. Cancer Immunology, Immunotherapy, 2021, 70, 2529-2543.	4.2	15
4	Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU). Journal of Infection and Chemotherapy, 2021, 27, 1169-1180.	1.7	4
5	Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High. OncoTargets and Therapy, 2021, Volume 14, 4853-4858.	2.0	4
6	Primary aortoduodenal fistula in testicular cancer: A fatal complication associated with retroperitoneal lymph node metastasis. Urology Case Reports, 2021, 39, 101746.	0.3	1
7	Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin. In Vivo, 2021, 35, 3107-3110.	1.3	4
8	A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma. International Journal of Clinical Oncology, 2020, 25, 354-361.	2.2	7
9	Laparoscopyâ€assisted vasovasostomy for postâ€herniorrhaphy vas deferens obstruction. IJU Case Reports, 2020, 3, 72-75.	0.3	0
10	The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients. Journal of Infection and Chemotherapy, 2020, 26, 418-428.	1.7	16
11	TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. PLoS ONE, 2019, 14, e0220173.	2.5	6
12	Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus. Journal of Infection and Chemotherapy, 2019, 25, 413-422.	1.7	16
13	The resonanceÂ® metallic ureteral stent in the treatment of malignant ureteral obstruction: a prospective observational study. BMC Urology, 2019, 19, 137.	1.4	13
14	Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-GuÃ©rin induce antitumor immunity in a syngeneic murine bladder cancer model. PLoS ONE, 2019, 14, e0209196.	2.5	9
15	Multiplex PCR in noninvasive prenatal diagnosis for FGFR3â€related disorders. Congenital Anomalies (discontinued), 2019, 59, 4-10.	0.6	4
16	Bacillus Calmetteâ€“GuÃ©rin strain differences as the basis for immunotherapies against bladder cancer. International Journal of Urology, 2018, 25, 405-413.	1.0	18
17	High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors. International Journal of Urology, 2018, 25, 457-462.	1.0	10
18	Possible risk of overestimation of renal function using cystatin C-based eGFR in testicular cancer survivors treated with cisplatin-based chemotherapy. Clinical and Experimental Nephrology, 2018, 22, 727-734.	1.6	3

#	Article	IF	Citations
19	A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study. BMC Cancer, 2018, 18, 290.	2.6	1
20	Oral administration of cernitin pollen extract (Cernilton^{Â®}) for 30 days might be useful to avoid unnecessary biopsy in prostate biopsy candidates: A preliminary study. International Journal of Urology, 2018, 25, 479-485.	1.0	8
21	Impact of Living at the Japanese Antarctic Research Expedition Base on Urinary Status. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 27-31.	1.3	2
22	Systemic transduction of p16INK4a antitumor peptide inhibits lung metastasis of the MBTâ€‘2 bladder tumor cell line in mice. Oncology Letters, 2018, 17, 1203-1210.	1.8	1
23	Biomarkers for precision medicine in bladder cancer. International Journal of Clinical Oncology, 2017, 22, 207-213.	2.2	30
24	Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clinical and Experimental Nephrology, 2017, 21, 732-740.	1.6	14
25	Epidemiology of urothelial carcinoma. International Journal of Urology, 2017, 24, 730-734.	1.0	164
26	Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer. Japanese Journal of Clinical Oncology, 2017, 47, 67-73.	1.3	15
27	Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Japanese Journal of Clinical Oncology, 2016, 46, 468-474.	1.3	4
28	The clinical presentation and favorable prognosis of patients with isolated metachronous brain metastasis from germ cell tumors. Japanese Journal of Clinical Oncology, 2016, 46, 1047-1052.	1.3	2
29	Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study. Prostate International, 2016, 4, 140-144.	2.3	0
30	Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). International Journal of Clinical Oncology, 2016, 21, 1142-1149.	2.2	0
31	DNA methyltransferase-3 like protein expression in various histological types of testicular germ cell tumor. Japanese Journal of Clinical Oncology, 2016, 46, 475-481.	1.3	6
32	Laparoscopic Versus Open Nephroureterectomy in Muscle-Invasive Upper Tract Urothelial Carcinoma: Subanalysis of the Multi-Institutional National Database of the Japanese Urological Association. Journal of Endourology, 2016, 30, 520-525.	2.1	28
33	Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. Prostate International, 2015, 3, 87-92.	2.3	9
34	Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. Japanese Journal of Clinical Oncology, 2015, 45, 867-873.	1.3	17
35	Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. Japanese Journal of Clinical Oncology, 2015, 46, hyv180.	1.3	12
36	Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2015, 20, 1026-1034.	2.2	37

#	Article	IF	Citations
37	Occurrence of infection following prostate biopsy procedures in Japan. Journal of Infection and Chemotherapy, 2014, 20, 232-237.	1.7	28
38	Nanoparticulation of BCG-CWS for application to bladder cancer therapy. Journal of Controlled Release, 2014, 176, 44-53.	9.9	66
39	Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model. Journal of Controlled Release, 2014, 196, 161-167.	9.9	20
40	Adverse Reactions Related to Treatment Compliance During BCG Maintenance Therapy for Non-muscle-invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 2013, 43, 827-834.	1.3	14
41	<scp>B</scp>acillus <scp>C</scp>almetteâ€“<scp>G</scp>uerin (<scp>BCG</scp>) immunotherapy for bladder cancer: Current understanding and perspectives on engineered <scp>BCG</scp> vaccine. Cancer Science, 2013, 104, 22-27.	3.9	131
42	Analysis of tolerability of intravesical bacillus Calmette-GuÃ©rin (BCG) therapy in non-muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2012, 30, e15004-e15004.	1.6	0
43	The liposomeâ€incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmetteâ€GuÃ©in can directly enhance the susceptibility of cancer cells to lymphokineâ€activated killer cells through upâ€regulation of naturalâ€killer group 2, member D ligands. BJU International, 2011, 108, 1520-1526.	2.5	12
44	The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Research, 2011, 31, 2065-71.	1.1	28
45	Immunoprotection against murine bladder carcinoma by octaarginineâ€modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmetteâ€GuÃ©rin. BJU International, 2009, 103, 686-693.	2.5	21
46	Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling. BJU International, 2006, 97, 860-864.	2.5	30
47	YW2-07 Virulence factors in Uropathogenic Escherichia coli (Young Urologist Research Workshop). Japanese Journal of Urology, 2004, 95, 297.	0.1	0
48	The Limited Efficacy of Methotrexate, Actinomycin D and Cisplatin (MAP) for Patients with Advanced Testicular Cancer. Japanese Journal of Clinical Oncology, 2003, 33, 391-395.	1.3	10
49	Identification of a type III secretion system in uropathogenicEscherichia coli. FEMS Microbiology Letters, 2002, 212, 221-228.	1.8	30
50	Type 1, P and S fimbriae, and afimbrial adhesin I are not essential for uropathogenicEscherichia colito adhere to and invade bladder epithelial cells. FEMS Immunology and Medical Microbiology, 2002, 33, 23-26.	2.7	38
51	Highâ€dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer. International Journal of Urology, 2000, 7, 258-262.	1.0	8